Three events should be kept separate when reading 2026 peptide policy: an advisory committee discussion, an enforcement policy and a drug approval. They have different legal and scientific meanings.

FDA’s July 23–24 Pharmacy Compounding Advisory Committee materials covered several nominated peptide substances. FDA states that advisory recommendations are nonbinding. A committee vote therefore is not, by itself, an approval of a finished medicine. FDA July 2026 Pharmacy Compounding Advisory Committee materials

The policy did not stop at the meeting

On October 30, 2026, the Federal Register published notice of an HHS peptide-compounding enforcement-discretion policy while the 503A bulk-substances list is developed through rulemaking. The notice describes the policy as draft/interim and nonbinding, and expressly states that compounded drugs are not FDA-approved. October 30 2026 Federal Register notice of HHS policy

The linked policy addresses limited circumstances involving specified substances and licensed pharmacies, federal facilities or physicians. It includes conditions and supporting requirements. It should not be summarized as unrestricted permission for consumer sales of research vials. HHS interim peptide compounding enforcement discretion policy

Keep access and evidence separate

A change in enforcement approach does not create new randomized clinical evidence. It also does not establish that a particular preparation is safe, effective or appropriate for every patient. Clinical claims still need support from studies of the relevant product and use.

Anyone making an operational decision should review the current policy, the exact substance and applicable state requirements with qualified counsel. The policy may be revisited, and the status of a specific activity cannot be inferred from a general headline.

AXON’s summary is deliberately narrow: there has been a material 2026 policy development, so older blanket descriptions may be stale. At the same time, “FDA approved” and “all peptides are legal” remain inaccurate shortcuts. A responsible explanation identifies the actor, document, date and precise type of decision before describing what changed.